SNS-595

DRUG3 trials

Sponsors

Sunesis Pharmaceuticals

Conditions

Carcinoma, Small CellNeoplasmsSmall Cell Lung Cancer

Phase 1

Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.

CompletedNCT00091585

Sunesis PharmaceuticalsNeoplasms

Start: 2004-06-30End: 2006-11-30Updated: 2007-05-10

Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors

CompletedNCT00094159

Sunesis PharmaceuticalsNeoplasms

Start: 2004-10-31Updated: 2007-05-10

Phase 2

Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer

CompletedNCT00298896

Sunesis PharmaceuticalsCarcinoma, Small Cell, Small Cell Lung Cancer

Start: 2006-02-28End: 2008-06-30Updated: 2018-07-26